Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
BAA-23-100-SOL-00004 · HEALTH AND HUMAN SERVICES, DEPARTMENT OF
A federal solicitation, performed in Jersey City, NJ. AwardCast estimates what this specific solicitation will close for, before you bid.
Comparable recent awards
| Winner | Award value | Offers | Date |
|---|---|---|---|
| Detail available to signed-in users. | |||
Questions
What is solicitation BAA-23-100-SOL-00004?
Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula, issued by HEALTH AND HUMAN SERVICES, DEPARTMENT OF, performed in Jersey City, NJ.
Explore the market
Forecast Report — what a specific solicitation will close for: the predicted price range, the competition to expect, and comparable awards already closed. Before you price your bid.
Every forecast is scored against the real award once it becomes public. See the track record.
Closed awards from public federal data, not the forecast. One email, no account.
Or get the forecast for this solicitation — $49, one report.